Related Experiment Video

Updated: Jun 13, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Treating multiple sclerosis with fingolimod or intramuscular interferon

Carlo Pozzilli1, Luca Prosperini, Giovanna Borriello

  • 1La Sapienza University, S. Andrea Hospital, Multiple Sclerosis Centre, Department of Neurological Sciences, Viale dell'Università, 30, 00185 Rome, Italy. carlo.pozzilli@uniroma1.it

Expert Opinion on Pharmacotherapy
|April 30, 2010
PubMed

Insights

Oral fingolimod demonstrated superior efficacy in reducing relapses and MRI-detected activity compared to interferon beta-1a in relapsing remitting multiple sclerosis patients. However, safety concerns necessitate further risk-benefit evaluation for this multiple sclerosis treatment.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • The TRANSFORMS study evaluated oral fingolimod (0.5 and 1.25 mg/day) versus intramuscular interferon beta-1a (30 microg) in 1292 relapsing remitting multiple sclerosis patients over 12 months.
  • This double-blind trial aimed to compare the efficacy and safety of these multiple sclerosis therapies.

Discussion:

  • Both fingolimod doses significantly reduced relapse rates and magnetic resonance imaging-detected disease activity compared to interferon beta-1a.
  • No significant impact on disability progression was observed for any treatment arm.
  • Higher-dose fingolimod was associated with increased adverse events, including infections, bradyarrhythmias, lymphopenia, macular edema, skin cancer, and liver enzyme elevation, leading to higher discontinuation rates.

Key Insights:

  • Oral fingolimod offers superior efficacy over intramuscular interferon beta-1a for managing relapsing remitting multiple sclerosis.
  • Safety concerns, particularly with the higher fingolimod dose, require careful consideration and long-term monitoring.
  • The study highlights a complex risk-benefit profile for oral fingolimod in multiple sclerosis treatment.

Outlook:

  • Further long-term studies are essential to fully ascertain the risk-benefit ratio of oral fingolimod.
  • The potential role of oral fingolimod as a first-line or alternative therapy for multiple sclerosis requires further investigation.
  • Ongoing research should focus on optimizing fingolimod dosing and monitoring strategies to mitigate adverse events.

More Related Videos

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...